



**Pan American
Health
Organization**



Regional Office of the
World Health Organization



PAN AMERICAN NETWORK FOR DRUG
REGULATORY HARMONIZATION

Common Requirements for Drug Registration

(DRAFT)





WORKING GROUP ON DRUG REGISTRATION



Members*:

Esperanza Briceño, Group Coordinator, Director de Drogas, Medicamentos y Cosméticos, MSP de Venezuela

Victoria de Urioste, Ministerio de Salud de Bolivia

Izabella Núñez Chinchilla, Directora Asistente de Medicamentos, ANVISA, Brasil

Viviente Lockhart, Director Bahamas Nacional Drug Agency

Pilar Alfredo Lagos, Ministerio de Salud, El Salvador

Pamela Milla, Jefe Departamento Control Nacional. Instituto Salud Pública de Chile

Justina Molzon, FDA-USA

Rosa Angela De Sario, FIFARMA

Miguel Maito, ALIFAR

Observers:

Ricardo Bolaños, ANMAT, Argentina

Secretariat:

Rosario D'Alessio, OPS/OMS

* Current Members in bold

PAN AMERICAN NETWORK FOR DRUG REGULATORY HARMONIZATION

WORKING GROUP ON DRUG REGISTRATION

COMMON REQUIREMENTS FOR DRUG REGISTRATION

Requirements for Drug Registration	New Entity	New Formulations	New Strength	New Association	Pharmaceutical equivalent: Generic	Pharmaceutical Equivalent: Similar	Drug Registration Renewal	Biologics: Vaccines	Biologics: Recombinant	Blood Products	Renewal of Biologics
I. Establishment General Information											
1. License holder/Market Authorization holder	√	√	√	√	√	√	√	√	√	√	
2. Holder address, phone, Fax , E-mail	√	√	√	√	√	√	√	√	√	√	
3. Legal representative in the country	√	√	√	√	√	√	√	√	√	√	
4. Legal rep address, phone, Fax , E-mail	√	√	√	√	√	√	√	√	√	√	
5. Name of the Active pharmaceutical Ingredient's manufacturer	√	√	√	√	√	√	√	√	√	√	
6. Active pharmaceutical Ingredient's manufacturer Address, phone, Fax , E-mail	√	√	√	√	√	√	√	√	√	√	
7. Name of the finished product's manufacturer	√	√	√	√	√	√	√	√	√	√	
8. Finished product's											

Requirements for Drug Registration	New Entity	New Formulations	New Strength	New Association	Pharmaceutical equivalent: Generic	Pharmaceutical Equivalent: Similar	Drug Registration Renewal	Biologics: Vaccines	Biologics: Recombinant	Blood Products	Renewal of Biologics
	manufacturer address, Phone, Fax , E-mail	√	√	√	√	√	√	√	√	√	√
II. Establishment Technical Information											
9. Licensing of the Manufacturer	√	√	√	√	√	√	√	√	√	√	
10. Good Manufacturing Practices (GMP) Certificate of the Pharmaceutical Active Ingredient Manufacturer	To be analyzed by WGI/ GMP	To be analyzed by WGI/ GMP	To be analyzed by WGI/ GMP	To be analyzed by WGI/ GMP	To be analyzed by WGI/ GMP	To be analyzed by WGI/ GMP	To be analyzed by WGI/ GMP	To be analyzed by WGI/ GMP	To be analyzed by WGI/ GMP	√	
11. Good Manufacturing Practices (GMP) Certificate of the finished product manufacturer as requisite for marketing authorization (licensing)	√	√	√	√	√	√	√	√	√	√	
12. Certificate of pharmaceutical product (CPP) as in WHO model	√	√	√	√	√	√	√	√	√	√	
13. Licensing for alternative product manufacturer	√	√	√	√	√	√	√	Should send Study of validation and qualification of producers	√	√	
14. Licensing for alternative product packaging								√	√	√	
15. If any of the two											

Requirements for Drug Registration	Requirements for Drug Registration							Biologics: Vaccines	Biologics: Recombinant	Blood Products	Renewal of Biologics
	New Entity	New Formulations	New Strength	New Association	Pharmaceutical equivalent: Generic	Pharmaceutical Equivalent: Similar	Drug Registration Renewal				
previous questions are affirmative, the location of the establishments are stated	√	√	√	√	√	√	√	√	√	√	
16. The responsible for the batch release must be stated NOTE: To be analyzed by WG / GMP	√	√	√	√	√	√	√	√	√	√	
III. Product General Information											
17. Brand name	√	√	√	√	-	√	√	√	√	√	
18. Generic name (INN)	√	√	√	√	√	√	√	√	√	√	
19. Presentations (for marketing)	√	√	√	√	√	√	√	√	√	√	
20. Strengths	√	√	√	√	√	√	√	√	√	√	
21. Dosage Forms	√	√	√	√	√	√	√	√	√	√	
22. Route of Administration	√	√	√	√	√	√	√	√	√	√	
23. Proposed marketing/dispensing status: prescription /OTC	√	√	√	√	√	√	√	√	√	√	
24. Description of packaging materials (primary & secondary)	√	√	√	√	√	√	√	√	√	√	

Requirements for Drug Registration	New Entity	New Formulations	New Strength	New Association	Pharmaceutical equivalent: Generic	Pharmaceutical Equivalent: Similar	Drug Registration Renewal	Biologics: Vaccines	Biologics: Recombinant	Blood Products	Renewal of Biologics
V. Product Legal Information											
25. Authorization to represent the product' holder in the country where the product is to be registered	√	√	√	√	√	√	√	√	√	√	
26. Certification of the Technical Director	√				√	√	√	√	√	√	
V. Technical Information of the Pharmaceutical Active Ingredient											
27. International Non – Proprietary Name (INN)	√	√	√	√	√	√	√	√	√	√	
28. ATC Classification code	√	√	√	√	√	√	√	√	√	√	
V. Physical-Chemical Characteristics of the Pharmaceutical Active Ingredient											
29. Chemical Name	√	√	√	√	√	√	√	when is required	√	when is required	
30. Molecular formula	√	-	-	-	-	-	-	when is required	when is required	when is required	
31. Structural Formula	√	-	-	-	-	-	-	when is required	when is required	when is required	

Requirements for Drug Registration	New Entity	New Formulations	New Strength	New Association	Pharmaceutical equivalent: Generic	Pharmaceutical Equivalent: Similar	Drug Registration Renewal	Biologics: Vaccines	Biologics: Recombinant	Blood Products	Renewal of Biologics
								when is required			
32. Molecular weight	√	-	-	-	-	-	-	when is required	√	√	
33. Organoleptic Characteristics	√	√	√	√	√	√	-	Chemical name, formulates molecular structural can be required in case of vaccine synthetic, fractional or modified and recombinant blood derivative.			
34. Physical Characteristics	√	√	√	√	√	√	-	√	√	√	
35. Chemical Characteristics	√	√	√	√	√	√	-	√	√	√	
36. Synthesis Pathway (Origin strain and substratum utilized in the production of the vaccine and process of attenuation, inactivation, conjugation, division according to case. In blood derivatives Master File Plasma, relating to the origin and control of the plasma, methods of viral inactivation. Recombinant, origin transformed strain and controls)	√	-	-	-	-	-	-	√	√	√	
37. Impurities	√	√	√	√	√	√	-	√	√	√	
38. Degradation substances by-products	√	√	√	√	√	√	-	√	√	√	
39. Specifications for release	√	√	√	√	√	√	-	√	√	√	
40. Stability Test and validity period	√	√	√	√	√	√	-	√	√	√	
41. Analytical Method	√	√	√	√	√	√	-	√	√	√	

Requirements for Drug Registration	Requirements for Drug Registration							Biologics			
	New Entity	New Formulations	New Strength	New Association	Pharmaceutical equivalent: Generic	Pharmaceutical Equivalent: Similar	Drug Registration Renewal	Biologics: Vaccines	Biologics: Recombinant	Blood Products	Renewal of Biologics
42. Validation of analytical method	√	√	√	√	√	√	-	√	√	√	
VI. Finished Product Technical information											
43. Documentation on product galenic development	√	√	√	√	√	√	-	√	√	√	
44. Formula	√	√	√	√	√	√	-	√	√	√	
45. Manufacture Method with control method during the process	√	√	√	√	√	√	-	√	√	√	
46. Excipients Physical-chemical characteristics	√	√	√	√	√	√	-	√	√	√	
47. Control methods of the final product	√	√	√	√	√	√	-	√	√	√	
48. Specifications for release	√	√	√	√	√	√	-	√	√	√	
49. Stability test according to the climate zone of the country (Vaccines should include rapid stability)	√	√	√	√	√	√	-	√	√	√	
50. Storage conditions	√	√	√	√	√	√	-	√	√	√	
51. Shelf life / validity period	√	√	√	√	√	√	-	√	√	√	
52. Quality Monitoring of the first batch of the marketed product (All lot for vaccines and blood derivatives)	√	√	√	√	√	√	-	√	√	√	

Requirements for Drug Registration	New Entity	New Formulations	New Strength	New Association	Pharmaceutical equivalent: Generic	Pharmaceutical Equivalent: Similar	Drug Registration Renewal	Biologics: Vaccines	Biologics: Recombinant	Blood Products	Renewal of Biologics
VIII. Technical Bio-pharmaceutics Information											
53. Dissolution test (for those dosage forms that thus require it)	√	√	√	√	√	√	-	-	lyophilized	lyophilized	
54. <i>In Vitro</i> BE studies (dissolution profile) NOTE: Is affirmative As established by WG/BE	√	√	√	√	√	√	√	-	-	-	
55. <i>In Vivo</i> BE Studies NOTE: Is affirmative As established by WG/BE	√	√	√	√	√	√	√	-	-	-	
IX. Pre-Clinical Data											
56. General Toxicology	√	-	-	-	-	-	-	√	√	√	
57. Specific Toxicology	√	-	-	-	-	-	-	When applies	When applies	-	
58. Pharmacodynamics Studies (including microbiologic studies)	√	-	-	-	-	-	-	√	√	√	
59. Pharmacokinetics Studies	√	-	-	-	-	-	-	-	√	√	

Requirements for Drug Registration	New Entity	New Formulations	New Strength	New Association	Pharmaceutical equivalent: Generic	Pharmaceutical Equivalent: Similar	Drug Registration Renewal	Biologics: Vaccines	Biologics: Recombinant	Blood Products	Renewal of Biologics
	X. Clinical Information										
60. Summary	√	when corresponds	when corresponds	when corresponds	-	-	-	√	√	√	
61. Phase I studies (pharmacokinetics in human and bioavailability)	√	-	-	√	-	-	-	√	√	√	
62. Phase II studies	√	√	√	√	-	-	-	√	√	√	
63. Phase III Studies	√	√	√	√	-	-	-	√	√		
64. Phase IV studies (Information on Safety)		√	√	Separate by product	√	√	√	√	√	√	
65. Special populations studies	√	-	-	-	-	-	-	When apply	When apply		
XI. Labeling/required documents											
66. Draft of the product final label	√	√	√	√	√	√	-	√	√	√	
67. Final packaging of marketing of the product	-	-	-	-	-	-	√	-	-	-	

Requirements for Drug Registration	New Entity	New Formulations	New Strength	New Association	Pharmaceutical equivalent: Generic	Pharmaceutical Equivalent: Similar	Drug Registration Renewal	Biologics: Vaccines	Biologics: Recombinant	Blood Products	Renewal of Biologics
68. Sample of the label final art with the first lot of verification	√	for the first lot of marketing	√	√	√	√	-	√	√	√	
XII. Information to include in the Primary Packaging											
69. Brand Name	√	√	√	√	-	√	-	√	√	√	
70. Generic name (INN)	√	√	√	√	√	√	-	√	√	√	
71. Strengths	√	√	√	√	√	√	-	√	√	√	
72. Dosage Form	√	√	√	√	√	√	-	√	√	√	
73. Expiration date	√	√	√	√	√	√	-	√	√	√	
74. Batch number	√	√	√	√	√	√	-	√	√	√	
XIII. Information to include in the Secondary Packaging											
75. Brand name	√	√	√	√		√	-	√	√	√	
76. Generic name (INN)	√	√	√	√	√	√	-	√	√	√	

Requirements for Drug Registration	New Entity	New Formulations	New Strength	New Association	Pharmaceutical equivalent: Generic	Pharmaceutical Equivalent: Similar	Drug Registration Renewal	Biologics: Vaccines	Biologics: Recombinant	Blood Products	Renewal of Biologics
77. Strength	√	√	√	√	√	√	-	√	√	√	
78. Dosage Form	√	√	√	√	√	√	-	√	√	√	
79. Content	√	√	√	√	√	√	-	√	√	√	
80. Registration number	√	√	√	√	√	√	-	√	√	√	
81. Expiration date	√	√	√	√	√	√	-	√	√	√	
82. Manufacturer	√	√	√	√	√	√	-	√	√	√	
83. Name of the Responsible Professional	√	√	√	√	√	√	-	√	√	√	
84. Storage conditions	√	√	√	√	√	√	-	√	√	√	
85. Preparation Method	-	Drugs without prescription	Only OTC	Only OTC	Only OTC	Only OTC	-	-	-	-	
86. Directions for use / Instructions		Only OTC	Only OTC	Only OTC	Only OTC	Only OTC	-	√	√	√	
87. Therapeutics use	√	√	√	√	√	√	-	√	√	√	
88. Dosages	-	√ Only OTC	√ Only OTC	√ Only OTC	√ Only OTC	√ Only OTC	-	-	-	-	
89. Prescription and use	√	√	√	√	√	√	-	√	√	√	

Requirements for Drug Registration	New Entity	New Formulations	New Strength	New Association	Pharmaceutical equivalent: Generic	Pharmaceutical Equivalent: Similar	Drug Registration Renewal	Biologics: Vaccines	Biologics: Recombinant	Blood Products	Renewal of Biologics
90. Maximum dose for 24 hours	-	Only OTC	Only OTC	Only OTC	Only OTC	Only OTC	-	-	-	-	
91. Information on “See the doctor if the symptoms worsen”	-	Only OTC	Only OTC	Only OTC	Only OTC	Only OTC	-	-	-	-	
92. Warnings	√	√	√	√	√	√	-	√	√	√	
93. Distinctive Identifications		Only OTC	Only OTC	Only OTC	Only OTC	Only OTC	-				
94. Batch number	√	√	√	√	√	√	-	√	√	√	
XIV. Information to include in Insert or Prospect											
95. Brand name	√	√	√	√	-	√	√	√	√	√	
96. Generic name (INN)	√	√	√	√	√	√	√	√	√	√	
97. Content (marketed presentations)	√	√	√	√	√	√	-	√	√	√	
98. Strengths	√	√	√	√	√	√	-	√	√	√	
99. Route of administration	√	√	√	√	√	√	-	√	√	√	

Requirements for Drug Registration	New Entity	New Formulations	New Strength	New Association	Pharmaceutical equivalent: Generic	Pharmaceutical Equivalent: Similar	Drug Registration Renewal	Biologics: Vaccines	Biologics: Recombinant	Blood Products	Renewal of Biologics
100. Length of treatment	-	Only OTC	Only OTC	Only OTC	Only OTC	Only OTC	-	√	√	√	
101. Use in pregnancy and breast feeding	√	√	√	√	√	√	-	√	√	√	
102. Dosage Forms	√	√	√	√	√	√	-	√	√	√	
103. Manufacturer	√	√	√	√	√	√	-	√	√	√	
104. Directions for use	√	√	√	√	√	√	-	√	√	√	
105. Therapeutic use	√	√	√	√	√	√	-	√	√	√	
106. Dosages	√	√	√	√	√	√	-	√	√	√	
107. Maximum dose in 24 hours	-	Only OTC	Only OTC	Only OTC	Only OTC	Only OTC	-	-	-	-	
108. Information “see the doctor if symptoms worsen”	-	Only OTC	Only OTC	Only OTC	Only OTC	Only OTC	-	-	-	-	
109. Warnings	√	√	√	√	√	√	-	√	√	√	
110. Precautions	√	√	√	√	√	√	-	√	√	√	
111. Adverse Reactions	√	√	√	√	√	√	-	√	√	√	
112. Interactions	√	√	√	√	√	√	-	√	√	√	

Requirements for Drug Registration	New Entity	New Formulations	New Strength	New Association	Pharmaceutical equivalent: Generic	Pharmaceutical Equivalent: Similar	Drug Registration Renewal	Biologics: Vaccines	Biologics: Recombinant	Blood Products	Renewal of Biologics
113. Overdose	√	√	√	√	√	√	-	√	√	√	
114. Contraindications	√	√	√	√	√	√	-	√	√	√	
115. Conservation of the product / Storage conditions		√	√	√	√	√	-	√	√	√	